INTRODUCING SnapLVV
Get the right amount of lentiviral vector (LVV) just the way you need it – fast and easy.
BECAUSE WAITING IS WASTING
When it could take up to two years to create the fundamental material required to get your therapy to clinic, that critical bottleneck risks putting you behind schedule. And if your small-batch vector provider doesn’t have the infrastructure or regulatory expertise to guide you past a Phase I trial, you may have to switch partners midstream, piling up additional costs and delays.
It’s about time for a more viable alternative to accelerate your immune cell therapy right from the start.
A SMARTER QUICKER WAY FORWARD TO LVV
Enter SnapLVV powered by Resilience, an off-the-shelf process to get your cell therapy ready for first-in-human studies without time-consuming development work. We’ve completed the framework for the process and analytics, so you can plug into a platform that’s ready to work for you. With SnapLVV, everything is set up to happen faster by helping you reach critical milestones for your studies, data readouts, and/or fundraising sooner.
Capitalize on streamlined processes optimized for LVV manufacturing through a plug-and-play approach.
Secure a single batch that has all the material you need to get you through your Phase I studies.
Maintain continuity through the same cell line and analytics in scaling late-phase/commercial processes.
Forecast budgets easier and reduce purchasing hassles through straightforward pricing that includes raw materials.
Help future-proof your program by leveraging our team’s understanding of key operational and regulatory considerations.
HOW TO PRESS "GO" WITH SnapLVV
If SnapLVV is the right fit for your LVV manufacturing needs, here’s a snapshot of how our partnership with you can take shape.
WHAT YOU PROVIDE
- GOI Plasmid in a kanamycin backbone
- Transgene information for product specific assays and biosafety evaluation
WHAT WE PROVIDE
- Cell line
- Packaging plasmids
- GOI plasmid procurement support (optional)
- All raw materials
- Equipment
- Resilience suspension LVV manufacturing platform
WHAT WE DO
- GOI procurement (optional)
- 20L Process establishment run for platform suitability
- 20L Demo run
- 20L GMP run
- Analytics using qualified methods matched to offering
- Phase-appropriate regulatory support
WHAT YOU RECEIVE
- cGMP LVV product released in less than 12 months when all raw materials (including client-supplied GOI plasmid) are available up front
- Bundled raw and starting materials excluding GOI
- Quality reviewed reports including CofA
- Path to commercialization
Not every project is an ideal candidate for SnapLVV, especially when your innovation would benefit from a custom development program with Resilience. If this sounds like you, reach out and we can discuss additional options.
“The SnapLVV offering provides an expedited path for cell therapy innovators to get to the clinic and first-in-human studies. The scientists behind the development of this service offering are proud to help address a gap in the biomanufacturing industry and develop a cost-effective program that can scale past Phase I. We are most excited that SnapLVV will help organizations provide life-saving therapies to patients in need.”
Resilience Principal Scientist, Vector Development
